SHTDF: AI 评分 45/100 — AI 分析 (4月 2026)

Sinopharm Group Co. Ltd. is a leading pharmaceutical and healthcare product distributor in China. The company operates across pharmaceutical distribution, medical devices, retail pharmacy, and pharmaceutical production.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Sinopharm Group Co. Ltd., a major player in China's healthcare sector, distributes pharmaceuticals, medical devices, and healthcare products. Operating through multiple segments including retail pharmacy and pharmaceutical distribution, the company leverages strategic partnerships to enhance commercial capabilities and serves a vast network of hospitals, distributors, and retail outlets across the People's Republic of China.

SHTDF是做什么的？

Founded in 2003 and headquartered in Shanghai, Sinopharm Group Co. Ltd. has rapidly grown to become a significant distributor of pharmaceutical and medical products in China. As a subsidiary of Sinopharm Industrial Investment Co., Ltd., the company operates through four primary segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment is the cornerstone, distributing pharmaceutical products to hospitals, distributors, retail drug stores, and clinics, while also providing logistics and value-added services to manufacturers. The Medical Devices segment focuses on the distribution of a wide array of medical equipment. The Retail Pharmacy segment manages an extensive network of 10,259 retail pharmacies as of December 31, 2021, offering direct access to consumers. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Sinopharm's strategic partnership with I-Mab aims to bolster its commercialization capabilities. The company also provides a range of services including property rental, medical instrument distribution, IT development, and medical consultation, reinforcing its comprehensive presence in the healthcare industry.

SHTDF的投资论点是什么？

Sinopharm Group Co. Ltd. presents a compelling, albeit moderate, investment case due to its dominant position in China's pharmaceutical distribution market. With a P/E ratio of 8.52 and a dividend yield of 3.50%, the company offers potential value. A key growth catalyst is the increasing demand for healthcare products and services in China, driven by an aging population and rising income levels. The company's extensive distribution network and strategic partnerships, such as the one with I-Mab, enhance its commercial capabilities. However, a low profit margin of 1.2% and gross margin of 7.5% pose challenges. Investors should monitor the company's ability to improve profitability and navigate regulatory changes in the Chinese healthcare sector. The beta of 0.62 suggests lower volatility compared to the broader market.

SHTDF在哪个行业运营？

Sinopharm Group Co. Ltd. operates within China's rapidly expanding healthcare market, driven by increasing healthcare spending and an aging population. The pharmaceutical distribution industry is highly competitive, with key players including CNVVF, CNVVY, GNGBY, GZPHF, and MSMKF. Sinopharm's extensive distribution network and diversified business segments provide a competitive edge. The Chinese government's healthcare reforms and policies significantly impact the industry, creating both opportunities and challenges for companies like Sinopharm. The market is characterized by increasing demand for high-quality pharmaceuticals and medical devices, presenting growth avenues for well-positioned distributors.

Medical - Distribution

Healthcare

SHTDF有哪些增长机遇？

Expansion of Retail Pharmacy Network: Sinopharm can further expand its retail pharmacy network, particularly in underserved regions of China. With over 10,000 existing pharmacies, strategic expansion can capture a larger share of the retail pharmaceutical market, estimated to reach $450 billion by 2028. This expansion can be achieved through organic growth and strategic acquisitions, enhancing direct access to consumers and increasing revenue streams. Timeline: Ongoing.
Strategic Partnerships with International Pharmaceutical Companies: Forming strategic partnerships with international pharmaceutical companies allows Sinopharm to distribute innovative drugs and medical devices in China. This leverages Sinopharm's distribution network and provides access to cutting-edge products, addressing unmet medical needs and driving revenue growth. The market for imported pharmaceuticals in China is projected to reach $50 billion by 2027. Timeline: Ongoing.
Development of Value-Added Services: Enhancing value-added services, such as logistics, cold chain management, and data analytics, can differentiate Sinopharm from competitors. These services cater to the evolving needs of pharmaceutical manufacturers and healthcare providers, creating additional revenue streams and strengthening customer relationships. The market for pharmaceutical logistics in China is expected to reach $30 billion by 2026. Timeline: Ongoing.
Penetration into Rural Healthcare Markets: Expanding into rural healthcare markets presents a significant growth opportunity, as these regions often lack access to quality pharmaceuticals and medical devices. Sinopharm can leverage its distribution network to serve rural hospitals, clinics, and pharmacies, addressing healthcare disparities and tapping into a large, underserved market. The rural healthcare market in China is estimated to be worth $200 billion by 2025. Timeline: Upcoming.
Investment in Digital Healthcare Solutions: Investing in digital healthcare solutions, such as online pharmacies, telemedicine platforms, and patient management systems, can enhance Sinopharm's reach and improve customer engagement. These solutions cater to the growing demand for convenient and accessible healthcare services, driving revenue growth and strengthening Sinopharm's competitive position. The digital healthcare market in China is projected to reach $100 billion by 2027. Timeline: Upcoming.

Market capitalization of $8.21 billion indicates a substantial presence in the pharmaceutical distribution market.
P/E ratio of 8.52 suggests a potentially undervalued stock compared to industry peers.
Dividend yield of 3.50% offers an attractive income stream for investors.
Gross margin of 7.5% reflects the competitive pricing environment in the pharmaceutical distribution sector.
Extensive retail network of 10,259 pharmacies (as of December 31, 2021) provides a strong distribution channel.

SHTDF提供哪些产品和服务？

Wholesale distribution of pharmaceutical products to hospitals and distributors.
Retail sale of pharmaceuticals through a network of pharmacies.
Distribution of medical devices and equipment.
Provision of logistics and value-added services to pharmaceutical manufacturers.
Production and sale of pharmaceutical products, chemical reagents, and laboratory supplies.
Property rental and management.
Offering medical consultation and information technology development services.

SHTDF如何赚钱？

Generates revenue through the wholesale distribution of pharmaceutical products.
Earns income from the retail sale of pharmaceuticals through its pharmacy network.
Profits from the distribution of medical devices and equipment.
Provides value-added services, such as logistics and cold chain management, for additional revenue.
Manufactures and sells pharmaceutical products, chemical reagents, and laboratory supplies.

Hospitals and healthcare institutions.
Pharmaceutical distributors and wholesalers.
Retail pharmacies and drug stores.
Patients and consumers through its retail pharmacy network.
Pharmaceutical manufacturers seeking distribution services.

Extensive distribution network across China, providing broad market access.
Large network of retail pharmacies, offering direct access to consumers.
Strategic partnerships with pharmaceutical manufacturers, enhancing product offerings.
Established brand reputation and market presence in the Chinese healthcare industry.
Diversified business segments, reducing reliance on any single product or market.

什么因素可能推动SHTDF股价上涨？

Ongoing: Expansion of the retail pharmacy network to increase direct consumer access.
Ongoing: Strategic partnerships with international pharmaceutical companies to distribute innovative drugs.
Ongoing: Development of value-added services, such as logistics and cold chain management, to differentiate from competitors.
Upcoming: Penetration into rural healthcare markets to address healthcare disparities.
Upcoming: Investment in digital healthcare solutions, such as online pharmacies and telemedicine platforms.

SHTDF的主要风险是什么？

Ongoing: Intense competition from other pharmaceutical distributors in China.
Ongoing: Price pressures from government regulations on pharmaceutical pricing.
Potential: Supply chain disruptions affecting the availability of pharmaceutical products.
Potential: Counterfeit drugs and quality control issues impacting brand reputation.
Potential: Economic slowdown in China affecting healthcare spending.

SHTDF的核心优势是什么？

Extensive distribution network across China.
Large network of retail pharmacies.
Strategic partnerships with pharmaceutical manufacturers.
Diversified business segments.

SHTDF的劣势是什么？

Low profit margin compared to industry peers.
Reliance on the Chinese market.
Exposure to regulatory changes in the Chinese healthcare sector.
Potential supply chain disruptions.

SHTDF有哪些机遇？

Expansion into underserved rural markets.
Growth in the aging population and increasing healthcare spending.
Development of value-added services.
Investment in digital healthcare solutions.

SHTDF面临哪些威胁？

Intense competition from other pharmaceutical distributors.
Price pressures from government regulations.
Counterfeit drugs and quality control issues.
Economic slowdown in China.

SHTDF的竞争对手是谁？

China Resources Pharmaceutical Group Limited — A major competitor in pharmaceutical manufacturing and distribution. — (CNVVF)
Shanghai Pharmaceuticals Holding Co. Ltd. — Another key player in the Chinese pharmaceutical market. — (CNVVY)
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd — Competes in traditional Chinese medicine and pharmaceutical products. — (GNGBY)
Guangzhou Pharmaceutical Co Ltd — Focuses on pharmaceutical distribution and retail. — (GZPHF)
Minsheng Pharmaceutical Group Co Ltd — Engaged in pharmaceutical manufacturing and distribution. — (MSMKF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Wanyong Lian
Headquarters: Shanghai, CN
Employees: 108,217
Founded: 2011

AI Insight

AI analysis pending for SHTDF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Sinopharm Group Co. Ltd. do?

Sinopharm Group Co. Ltd. is a leading distributor of pharmaceutical products, medical devices, and healthcare products in China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. Its extensive distribution network serves hospitals, distributors, retail drug stores, and clinics. Additionally, Sinopharm provides logistics and value-added services to pharmaceutical manufacturers. The company also operates a large network of retail pharmacies and engages in the production and sale of pharmaceutical products and related supplies. Its strategic partnership with I-Mab enhances its commercial capabilities.

What do analysts say about SHTDF stock?

Analyst sentiment on SHTDF is currently pending AI analysis. Key valuation metrics include a P/E ratio of 8.52 and a dividend yield of 3.50%. Growth considerations revolve around the company's ability to expand its distribution network, capitalize on the growing demand for healthcare products in China, and navigate regulatory changes in the pharmaceutical industry. Investors should monitor the company's financial performance and strategic initiatives to assess its potential for long-term growth and profitability. The OTC market adds additional risk factors to consider.

What are the main risks for SHTDF?

The main risks for Sinopharm Group Co. Ltd. include intense competition from other pharmaceutical distributors, price pressures from government regulations, and potential supply chain disruptions. The company also faces the risk of counterfeit drugs and quality control issues, which could damage its brand reputation. Additionally, an economic slowdown in China could affect healthcare spending and impact the company's revenue. As an OTC stock, SHTDF carries additional risks related to liquidity, disclosure, and regulatory oversight.